Eduardo Cronemberger

Medical oncologist and clinical researcher.

[Eduardo Cronemberger @educronemberger]

@NEJM @RamalingamMD Dr. @RamalingamMD, very proud and honored to be co-author of this practice-changing trial, as a representative of a small Brazilian research center. Congratulations for you presentation.

[Eduardo Cronemberger @educronemberger]

Very proud to run this practice-changing trial in our research center at CRIO and honored by the co-authorship of the LAURA trial: Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC | New England Journal of Medicine https://t.co/jDyr2eYd53

[Paolo Tarantino @PTarantinoMD]

ESMO23 will have a relevant impact on the way we treat breast cancer. Practice will be changed, shaped and/or challenged by several of the studies presented this week in Madrid. Here’s a personal selection of 10 #ESMO23 breast cancer abstracts not to miss. #bcsm

[Eduardo Cronemberger @educronemberger]

Estudo que muda a prática clínica de imediato. Orgulho em ter contribuído como investigador desse importante trial.
A practice-changing trial. Proud to contribute as an investigator from Brazil in this important trial.

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Of the 160 pts who received any subsequent therapy in control arm, 104 had immunotherapy. Not 100% but some were driver positive. Mature EFS analysis sustained (EFS HR 0.59, median EFS 47.2m vs 18.3m). Fantastic, practice changing work @DoctorJSpicer @HwakeleeMD & team!

[Stephen V Liu, MD @StephenVLiu]

#ESMO23 Of the 160 pts who received any subsequent therapy in control arm, 104 had immunotherapy. Not 100% but some were driver positive. Mature EFS analysis sustained (EFS HR 0.59, median EFS 47.2m vs 18.3m). Fantastic, practice changing work @DoctorJSpicer @HwakeleeMD & team!

[Toni Choueiri, MD @DrChoueiri]

JUST IN: KEYNOTE-671 OS + for EFS AND OS!!!!
-NSCLC Stage II, IIIA or IIIB (T3-4N2)
-Pembrolizumab is the first PD1 drug with OS in a perioperative setting!
-Initially presented at #ASCO23
-Update at #ESMO23

https://t.co/kXYuYQYBo8

@OncoAlert @myESMO @OncBrothers

[Ilana Schlam @IlanaSchlam]

Managing adverse events of sacituzumab govitecan - effectively managing the toxicities of ADCs is critical to optimize patient care and treatment adherence.

Check out our new review! @stolaney1 @PTarantinoMD

https://t.co/lK3Xrgq5J6

[Pashtoon Kasi MD, MS @pashtoonkasi]

While we talk about time & financial toxicity, ☝🏾thing that’s finally official after a lot of advocacy is

OXALIPLATIN

1️⃣mg/m2/min
🆚
arbitrarily over 2 hours➖1️⃣2️⃣0️⃣ minutes.

👍🏾@AndreaCercek Dr. Saltz @ASCO @JCOOP_ASCO 2016!

Let’s challenge dogma!
Let me know if you do this.

[Dipesh Uprety MD FACP @DipeshUpretyMD]

Lung Cancer Sessions that you should not miss #ASCO23
#LCSM @BTFCancerNews @OncoAlert @OncBrothers

[The Good Life @LeadGoodLife]

8 powerful same thought visuals:

1.

[Paolo Tarantino @PTarantinoMD]

Resources from #ESMOBreast23 are already available on @myESMO OncologyPRO website! Great opportunity to review the new data and brilliant educational sessions held in these days in Berlin. https://t.co/BmT2HZLPx1

[Stephen V Liu, MD @StephenVLiu]

Now @JCO_ASCO: 2-year analysis of sotorasib in 174 pts with #KRAS G12C NSCLC from CodeBreaK 100. RR 41%, mDOR 12.3m, mPFS 6.3m, mOS 12.5m, 2y OS rate 33%, 23% with PFS ≥1y. Long term benefit just as likely with or without STK11 comutation.

https://t.co/4lK27cP9G3

[Paolo Tarantino @PTarantinoMD]

Excited for the upcoming #ESMOBreast23, which will feature impactful new data and many outstanding educational sessions. Wonderful job by Congress Co-Chairs @ErikaHamilton9, S. Delaloge & SB Kim plus the whole Scientific Committee. Here’s my personal top 10 oral presentations!👇

[Benjamin Besse @BenjaminBesseMD]

Impressive OS benefit with chemo-nivolumab vs. chemo before surgery for NSCLC (16.8% not resected). 63% are stage III: the magnitude of benefit echoes results of durvalumab after definitive chemorad in the PACIFIC study. IO cures 15% additional patients treated locally? #ELCC2023

[Eduardo Cronemberger @educronemberger]

@StephenVLiu @JCO_ASCO Really amazing! Should we stop Pembro after 35 cycles even in SD/PR (not CR) responders? No more room for continuous treatment, as in CM153?

[Chris Boettcher @chrisboettcher9]

80% of people are insulin resistant

It's a silent killer...

If you want to control the deadly condition you probably already have, read this:

[Krishan Jethwa @KrishanJethwa]

How do I decide?
Factor in risk of DM and pelvic recurrence (PR).
DM: elevated CEA, EMVI, N2, tumor deposit, BRAF
Pelvic: T4b, </= 1 mm from MRF/CRM, +LPLNs, <5 cm from verge
If ⬆️ DM, favor early chemo
If ⬆️ PR risk, favor LC-CRT
If W&W, LC-CRT first (pending AIO-18/NOM-era)
9/

[Dan Go @CoachDanGo]

Food is a drug & most people are addicts

We use food when we're sad.

We use food when we celebrate.

We use food to numb our stress levels.

We approach food much like addicts approach drugs & alcohol but because it's accepted no one wants to admit it.

[Sherene Loi, MD @LoiSher]

🚩Very young women do poorly from #Breastcancer 🤔. Here we characterise oncogenic drivers from >1200 patients BC samplesin the #SOFT trial to try to understand why. 1) women Dx <40yrs have sig. more HRD, CN amplification, TP53 mt and genomic instability

[Yakup Ergün @dr_yakupergun]

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study @JCO_ASCO

Pembro + ChT vs ChT
5y OS➡️18.4 vs 9.7% (HR:0.71)
5y PFS➡️10.8 vs 3.5% (HR:0.62)

ORR➡️62% vs 39%

@OncoAlert
https://t.co/ptelltrGFh